Reimbursement of orphan drugs in Belgium: what (else) matters? by Eline Picavet et al.
Picavet et al. Orphanet Journal of Rare Diseases 2014, 9:139
http://www.ojrd.com/content/9/1/139RESEARCH Open AccessReimbursement of orphan drugs in Belgium: what
(else) matters?
Eline Picavet1*, David Cassiman2 and Steven Simoens1Abstract
Background: Most orphan drugs do not meet traditional standards of cost-effectiveness. Yet, most orphan drugs
are reimbursed, which implies that other factors are taken into account at the time of reimbursement. To increase
accountability of decision-makers, there is a need for more transparency in the factors that play a role in
reimbursement decisions of orphan drugs. Therefore, the aim of this study is to use a combination of qualitative
research methods to examine which official and non-official factors influence reimbursement decisions for orphan
drugs in Belgium.
Methods: Six semi-structured interviews with past or present members of the Drug Reimbursement Committee
(DRC) were performed with a view to obtaining an overview of the potential factors influencing reimbursement.
Additionally, these presence of these factors was assessed in the reimbursement dossiers of all orphan drugs
(n = 64) for which an application for reimbursement was submitted to the National Institute for Health and
Disability Insurance in Belgium between January 2002 and July 2013.
Results: Different official (i.e. therapeutic value, budget impact, price and impact in clinical practice) and
non-official factors (i.e. pricing and reimbursement in other countries, interference by patient organisations and
experts, arguments related to quality of branded drug versus compounding, media attention, innovative character,
economic importance, ethical arguments and the political climate) may have influenced past reimbursement
decisions for orphan drugs in Belgium.
Discussion: The identification of factors influencing orphan drug reimbursement is a crucial step in the development of
a transparent and consistent framework which will guide future decision-making for reimbursement of orphan drugs.
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In Europe, rare diseases are defined as life-threatening
or chronically debilitating diseases with a prevalence of
50 out of 100000 individuals or less. Legislation is in
place to stimulate the development of so-called ‘orphan
drugs’ for the treatment of rare diseases. Incentives, such
as a 10-year period of market exclusivity, are intended to
increase the commercial value of orphan drugs by redu-
cing R&D expenses and shortening time-to-market [1].
Currently only 72 orphan drugs are marketed in the
European Union [2]. Pricing and reimbursement deci-
sions are a responsibility of the Member States of the
European Union which govern different policies. As a* Correspondence: eline.picavet@pharm.kuleuven.be
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unless otherwise stated.result, availability and access to orphan drugs still differs
throughout the European Union [3-7].
Because of their high prices, most orphan drugs do
not meet traditional standards of cost-effectiveness. Yet,
most orphan drugs are reimbursed, which implies that
other factors are taken into account at the time of reim-
bursement [8]. Rosenberg-Yunger et al. conducted
qualitative case studies to determine how drug advisory
committees made reimbursement decisions for two or-
phan drugs in Canada, Australia and Israel. Reimburse-
ment recommendations were made based on technical
factors (such as cost-effectiveness) as well as other fac-
tors (such as ethical considerations). The authors con-
cluded that insight in these other factors is necessary to
improve the reimbursement of future orphan drugs [9].
Cerri et al. examined how different factors influenceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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for Health Care and Clinical Excellence (NICE) in the
United Kingdom. The multivariate regression analysis
showed that only 26 percent of the variability in deci-
sions can be explained by four outcome variables (i.e.
superiority of the primary endpoint, the incremental
cost-effectiveness ratio (ICER), the number of pharma-
ceuticals appraised within the same appraisal and the
year of the appraisal). The results suggested that deci-
sions are influenced by the decision-making process,
the clinical evidence and by the socio-economic and
political context [10]. In England, drugs for very rare
diseases are assessed separately taking into account
broader criteria such as health gains, societal values and
impact on clinical practice [11]. The Belgian application
procedure for reimbursement of orphan drugs has been
described in detail in a report by the Belgian Health
Care Knowledge Centre [12]. Briefly, a pharmaceutical
company simultaneously submits a reimbursement dos-
sier to the Drug Reimbursement Committee (DRC) of
the National Institute for Health and Disability Insur-
ance (NIHDI) and a price demand to the Federal Public
Service (FPS) Economy. As orphan drugs are considered
an exception in class 1 (i.e. drug with an added value), a
budgetary impact study is required in the reimburse-
ment dossier but a cost-effectiveness analysis is not.
The DRC is composed of one (non-voting) chairman
and 30 members; 22 voting members (i.e. seven aca-
demics, eight representatives of the sickness funds, four
representatives of the physicians’ association, three rep-
resentatives of the pharmacists association) and eight
non-voting members (i.e. four representatives of the
Ministry of Public Health, of Social Affairs, of Budget
and of Economics Affairs, one representative of the
NIHDI, and two members of Pharma.be (representing
the pharmaceutical industry in Belgium), and one mem-
ber of Febelgen (representing the generic pharmaceut-
ical industry)). The DRC evaluates drug reimbursement
requests based on the five criteria: therapeutic value,
price, proposed reimbursement tariff, the importance of
the drug in clinical practice, and the budgetary impact
of the drug [13]. The DRC may decide to compose a
group of experts to evaluate the application. A proposal
for reimbursement is prepared by the DRC within 150
days after the application. The final decision is made by
the Minister of Social Affairs within 180 days, after ap-
proval of the Minister of Budget has been obtained.
After a negative advice, companies may enter into negotia-
tions for managed entry agreements (in which for ex-
ample, the pharmaceutical company refunds a predefined
percentage of the price for every unit sold) as defined by
the Royal Decree of December 21th, 2001 [14]. Dupont
and Van Wilder performed a qualitative analysis of Belgian
reimbursement dossiers of all orphan drugs with a specificfocus on the evidence related to the five reimbursement
criteria (therapeutic value, price, proposed reimbursement
tariff, the importance of the drug in clinical practice, and
the budgetary impact of the drug) [15]. They concluded
that factors other than the official criteria seem to play a
role in the decision-making process, thereby creating un-
certainty [13].
With a view to increasing accountability of decision-
makers, there is a need for more transparency in the
factors that are taken into account in reimbursement deci-
sions of orphan drugs [11]. Frameworks for the structured
analysis of reimbursement decisions have been proposed
[16,17]. These frameworks allow for comparison of the
decision-making process across health care systems and
technologies [18]. Analysis of reimbursement decisions
may reveal preferences of third party payers which deviate
from pre-defined processes [19]. However, further re-
search is needed to assess the validity and transferability of
these frameworks [18]. Also, it remains a challenge to inte-
grate concepts such as transparency and stakeholder in-
volvement in the framework [19]. While past studies
applied quantitative research methods, this study aims to
obtaining an alternative view of the same issue. Therefore,
the aim of this study is to use a combination of qualitative
research methods to examine which official and non-
official factors influence reimbursement decisions for or-
phan drugs in Belgium. Furthermore, we aim to document




Semi-structured interviews were used as they enable the
interviewer to elaborate on specific aspects or insights of
the interviewee or when certain aspects are unclear for
the researcher. A total of seven former or present mem-
bers of the DRC (both voting and non-voting members)
were identified through selective expert sampling (i.e.
participants with an expert opinion on the subject mat-
ter) and snowball sampling (i.e. each participant was
asked to provide name(s) of possible other participants)
and were contacted by e-mail to participate. Further ar-
rangements, concerning time and place of the interview,
were made by e-mail or telephone. Semi-structured in-
terviews with six participants were conducted between
January 17th and February 5th 2014. A semi-structured
interview guide (Additional file 1: Appendix 1) was drafted
in the form of a table presenting a non-exhaustive list of
potential factors influencing reimbursement derived from
a literature review [10,13,15,20]. Respondents were asked
to comment on that list, provide real-life examples and
suggest changes or additions. Respondents participated
voluntarily and were not remunerated. Because of the na-
ture of the interviews, it was not required to seek approval
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participants and confidentiality of the answers were guar-
anteed. The interviews were audio-recorded and verbatim
transcribed. The interviews were analyzed using the QSR
NVivo 10 software according to the five stages of the
framework analysis: (1) familiarization (reading of the
transcripts and notes, listening to the digital recordings);
(2) identifying a framework; (3) indexing (i.e. applying the
framework to the data); (4) charting; and (5) interpreting
[21,22]. Appropriate quotes were selected from the tran-
scripts and translated from Dutch or French to English as
truthfully as possible. To facilitate reading, deleted parts of
the quotes are indicated by a “(…)” and additional infor-
mation is provided between square brackets. The coding
[I1, I2, …] identifies the interviewee.
Analysis of reimbursement dossiers
In the context of documenting the findings from the semi-
structured interviews with examples from Belgian orphan
drug reimbursement dossiers, the reimbursement dossiers
for all orphan drugs (n = 64) for which an application for
reimbursement was submitted to the NIHDI in Belgium
between January 2002 and July 2013 were analysed. In
Belgium, drug reimbursement dossiers are retained by the
NIHDI. The final decision made by the Minister of Social
Affairs and the evaluation report of the DRC are publicly
available since respectively January 2002 and April 2007.
Complete dossiers consist of the application for reimburse-
ment written by the pharmaceutical company, the first sci-
entific report by the DRC (Day 30 report), the evaluation
report by the DRC (Day 60 report), the decision on the
maximum price, the final proposal of the DRC (Day 150 re-
port), remarks and answers to the DRC’s questions by the
pharmaceutical company, the advice of the Finance in-
spector and the approval of the Minister of Budget and the
final decision made by the Minister of Social Affairs (Day
180). Examples provided in the Results section originate
from these documents. The complete dossiers were con-
sulted on-site between February 4th and February 24th 2014
after approval for research purposes was granted. The fol-
lowing information was extracted using a reporting tem-
plate: orphan drug; indication; applicant; dossier; start and
stop date of the reimbursement dossier; advice of the DRC;
advice of the financial inspector; approval of the Minister of
Budget; final decision; therapeutic value; clinical evidence;
applicability and user-friendliness; medical and social need;
price; budget impact; availability in other countries; special
patient characteristics; patient organisation; employment,
research and infrastructure in Belgium; support for research
and innovation; other peculiarities.
Results
The following provides an overview of the different fac-
tors which may have an influence on reimbursement oforphan drugs in Belgium. The DRC evaluates orphan drug
reimbursement requests based on official factors such as
therapeutic value, budget impact, price and importance of
the drug in the clinical practice. It is however conceivable
that other, non-official factors have an influence on the
decision-making by the DRC and the Minister of Social af-
fair. Each factor is documented with quotes from mem-
bers of the DRC and/or examples from Belgian orphan
drug reimbursement dossiers reflecting the views of the
DRC on the one hand and the applicant on the other.
Therapeutic value
Demonstrating therapeutic value for orphan drugs is often
complicated, for instance due to the use of surrogate end-
points, the small study population and the heterogeneous
presentation of rare diseases [23]. Furthermore, it is often
unclear how improvement in a hard or surrogate endpoint
translates into clinical benefit for patients thereby compli-
cating reimbursement decisions.
“There are also a few [orphan drugs] for which the
evidence is far less convincing, I’m thinking of some
enzyme replacement therapies”. [I1]
“The evidence for effectiveness is often not there”. [I2]
“Clinical progression, that’s an important factor! We
want to know, does the drug work? Statistical
significance is often a problem, because a lot of studies
lack power due to the number of patients. But also, is
it clinically relevant?” [I3]
Cost-effectiveness
No cost-effectiveness analysis is required for orphan drugs,
as such, the DRC does not have access to pharmaco-
economic data.
“We don’t have a pharmacoeconomic evaluation for
orphan drugs, we have no QALY, nothing!” [I4]
Budget impact
A budget impact analysis is required and is thoroughly
inspected by the DRC.
“The situation is like this, experts at the NIHDI check
the budget impact [provided by the pharmaceutical
company] and the parameters used to calculate that
budget impact, for example, if the firm says that there
are only 400 patients and our experts say that there
are in fact 2000, that will have a drastic effect on the
budget impact, so we need to find a balance”. [I5]
For example, the original budget impact for Xyrem®
amounted to €614,016, based on 52 treated patients.
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be at least fourfold (250), resulting in a budget impact
of €2,460,000. In other cases, the DRC was of the opinion
that additional expenses also need to be taken into account
in the budget impact analysis. For example, each patient
treated with Soliris® needs a meningococcal vaccination
(costing approximately €27 per vaccine), which was not
taken into consideration in the initial calculations.
“The estimation of budget impact is extremely
important, on the one hand to make the decision right
now, but on the other hand, in view of the future, we
can accept some deviations here and there, but
hopefully, there will be deviations in both directions,
both up and down”. [I2]
For instance, in 2008 the budget impact for Yondelis®
was estimated to amount to €443,044 for the treatment
of soft tissue sarcoma. In 2012, the budget impact
turned out to be much higher, (€3,177,766). Afterwards,
the ex-manufacturer price of the drug was reduced by
five percent, which should reduce the budget impact
to €2,960,089.
“We have to be careful, we have a certain budget, and
we try not to surpass those budgets, because that is at
the expense of other things”. [I5]
Some pharmaceutical companies attempt to highlight
the low(er) budget impact. To that end, the applicant of
Ilaris® added a comparison between the relatively low
budget impact of Ilaris® and other expensive orphan drugs
(Aldurazyme®, Elaprase®, Myozyme®,…). A similar over-
view was provided for Cystadane®. Additionally, it was
stated that the one-year budget impact for Cystadane®
would only represent 0.0011% of the total drug expend-
iture by the NIHDI.
Importance in clinical practice
The importance of a drug in clinical practice takes into
account factors such as therapeutic need (dependent on
patients’ age, mortality, disease burden,… ), place of the
drug in the clinical practice (availability of alternative
treatments) and adequacy of the package size. The age
and disease burden of patients is taken into account in
reimbursement decisions. Some interviewees acknow-
ledge difficulties in refusing reimbursement for young
patients with life-threatening diseases.
“I guess, if you have two options, approve or not
approve, then it is hard, knowing that there are only 5
children affected, not to approve the drug, because
that’s no longer a whole group of patients, but a very
specific situation”. [I1]“Something like that [disease burden] always gets
taken into account implicitly, never explicitly, in the
decision”. [I3]
“The age of patients, hmm, I guess. I think there is a
tendency to treat children rather than adults, someone
at the age of for example 60 years… There is a
tendency to treat younger people, to give them life
expectancy, rather than adults who, in that stadium,
often have a less debilitating disease”. [I3]
In some cases, an age limit is imposed because the regis-
tered indication is restricted to a selected age group.
“There was a drug, a long time ago, for the treatment of
multiple sclerosis, and was registered for use in patients
up to the age of 51. Therefore, it was only reimbursed up
to that age, … but we gave that up, because an upward
age limit is very delicate. But of course there is no
clinical evidence above that age”. [I2]
The DRC suggested limiting the reimbursement of
Adcetris® to patients below the age of 65. This was deemed
unethical by the pharmaceutical company, because Adce-
tris® is the only option for these patients (as they are less
likely to qualify for stem cell transplantation). Similarly,
the DRC suggested excluding patients below the age of
five from reimbursement of Aldurazyme®. The applicant
was of the opinion that young patients with the highest
treatment needs were excluded in that way.
The drugs’ place in clinical practice is also considered.
“If there is no other therapy, and this new one
potentially has some benefit, then it isn’t difficult, but
if there is an alternative, then the question is, has the
alternative been registered officially?” [I2]
Comparisons to alternative treatments are often made
in applications for reimbursement. For example, the appli-
cation for Tracleer® specifically mentions that Tracleer® is
the only oral treatment, suggesting an increased user-
friendliness. The application for Sprycel® mentions that
the use of the alternative treatment (Glivec®) can lead to
the emergence of resistance. Increasing dosages of Glivec®
are associated with more secondary effects and limited ef-
fectiveness. Therefore, Sprycel® would constitute a viable
alternative. The application for Vpriv® specifically men-
tions that there were shortages of Cerezyme® (the alterna-
tive drug) in 2009 and 2010, emphasizing the need for an
alternative treatment for Gaucher’s disease. Finally, there
are some cases in which the use of the new drug has been
established in other countries. For example, the applica-
tion dossier for Revlimid® mentions that the drug has
already been included in treatment guidelines from the
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Committee for Standards in Haematology and the UK
Myeloma Forum.
Lastly, the DRC also takes into consideration the rele-
vance of the package size as a function of the intended
therapy. Inadequate package size can lead to wasting, as
voiced by one of the interviewees.
“For some orphan drugs there are important rest
fractions. If for example dosing is based on mg per kg
[body weight], and you don’t need the second half of
the flacon, you will have to throw it away”. [I3]
For example, the DRC judged that the adequacy of
10 mg vials of Trisenox® is not suited to administer a
daily dose of 0.15 mg/kg because more than three quar-
ters of patients weigh more than 66 kg and would there-
fore need two vials per day. Similarly, the DRC feared
that the package of Mepact® (4 mg in 50 ml) would inev-
itably lead to important wasting. The applicant men-
tioned that the current dosage of Replagal® is better
suited for dosage titrations in patients with low body
weight as opposed to its alternative Fabrazyme®. In other
cases the dosage form was problematic.
“[about Siklos®] And they were big tablets, for kids of
two or three years of age, totally unsuitable … and not
even in a malleable form, or as a syrup”. [I2]
Price
The price of an orphan drug is often an issue of debate,
for instance if the price of the orphan drug is high com-
pared to the price of the pharmaceutical compounding
(e.g. Lysodren® versus mitotane, Firdapse® versus 3,4
DAP) or the price of the same drug for a more common
indication (e.g. Afinitor® versus Certican®, Revatio® versus
Viagra®). Unofficial prices are not communicated, as it
could have a negative impact on parallel trade. For ex-
ample, a request from the DRC to lower the price of
Vyndaqel by 30%, was turned down by the pharmaceut-
ical company because lowering the Belgian price would
lead to parallel export and would thereby endanger the
availability of the drug in Belgium.
“I think it’s a good thing we are carefully moving away
from the axiom “we don’t change the price of orphan
drugs”. But we can’t do that, as long as there is no
transparency in price setting. (…) I think it’s OK to
discuss the price of orphan drugs; this [current
situation] is no longer reasonable and sustainable. (…)
I can understand that, with parallel import and
export, it makes companies are not eager to
communicating unofficial prices, but it also makes
price setting very vague”. [I2]After a negative reimbursement advice, the pharma-
ceutical company may enter into negotiations for man-
aged entry agreements (MEAs). MEAs are intended to
balance the need for access to potentially beneficial or-
phan drugs with the uncertainty related to cost, safety,
effectiveness, [24]…
“Companies are open to that [managed entry
agreements], because it’s important for them to come
on the market at a certain price”. [I3]
MEAs are not part of the public domain. Only few
proposals for MEAs were found in the reimbursement
dossiers, for example in which the pharmaceutical
company suggests to provide a number of units for free
(e.g. Prialt®), to refund a predefined percentage of the
price for each unit sold if the budget exceeds a certain
threshold (e.g. Votubia®), or to refund a percentage of
the total turnover (e.g. Firazyr®). More details are not
communicated.
Price and reimbursement in other countries
Pricing and reimbursement conditions in other countries
are considered during the reimbursement decision. Fur-
thermore, these results suggest that other countries are
doing the same.
“Countries are finding each other in terms of
reimbursement, and we are not the difficult ones I
guess, not at all”. [I2]
“We always make a list of that, the price and
reimbursement conditions in other countries”. [I3]
“In certain cases, we take that into account, yes yes
yes, more and more, certainly related to price, we
look at what price is reimbursed elsewhere. (…)
We take a look at what’s happening in Europe (…)
The official price éh, we only see the official
price”. [I4]
For example, in the application dossier for Vpriv® it
is mentioned that a higher price than the one re-
quested in Belgium is fully reimbursed in the UK,
Germany, Switzerland, The Netherlands, Slovenia,
Denmark and Norway. Similarly, the application dos-
sier for Evoltra® states that the drug is already available,
without restrictive prescribing rules and at the same
price in inter alia UK, Ireland, Spain, France, the
Netherlands. The DRC issued a negative advice for the
reimbursement of Wilzin®, and pointed out that a simi-
lar negative assessment was also given by the Dutch
Health Care Insurance Board (CVZ).
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Officially, patient organizations are not consulted during
the decision-making process, but they can play an im-
portant role in creating awareness about disease-specific
problems and in understanding the impact of the drug
in daily life.
“They [patient organizations] are not consulted, but they
alert us of the different problems they experience, so we
can understand the problem. So they have a role when it
comes to creating awareness about the problem”. [I5]
“In those cases [when clinical impact is unclear],
patient organizations or doctors can play an
important role, because we, as members of the DRC
not always value the importance of clinical impact.
For example, it they say that patients are able to
walk ten meters instead of five, then yeah, is that
worth €200,000 a year? But if someone tells you that
because of that five extra meters, he can now be
independent, go to the toilet, do small domestic work,
… well that changes at a lot”. [I3]
“Pharmaceutical companies sometimes also add a
letter from the patient organization in the dossier. We
have dossiers with letters from patients stating that the
drug is important to them”. [I4]
For example, a letter from a patient organization,
highlighting the user-friendliness of the drug, was added
to the application dossier for Tobi Podhaler®. Similarly,
a handwritten letter by a patient describes her experi-
ences with other treatments and Exjade® and empha-
sizes the medical and social need for this adapted form
of iron chelation.
One interviewee had specific remarks.
“It’s not always more objective with patients there. (…)
To explain the practical course of something it can help,
but it’s definitely not always necessary. (…) Everyone [in
the DRC] signed a conflict of interest form, but patients
and patient organizations should do the same, because
there is a need for more transparency, how do most
patient organizations get funded?” [I2]Expert opinion
In the same way, letters from experts are sometimes added
to the application dossier with a view to confirming the
medical need and showing their support. For example a
list of arguments from Belgian experts, highlighting the
added value (i.e. the ease of dose adaptation) of Siklos®,
was added to the application dossier. Similarly, eight neo-
natologists signed a letter requesting reimbursement ofPedea® because it would have a substantial added value in
the treatment of patent ductus arteriosus.
Quality of the branded drug versus the pharmaceutical
compounding
Pharmaceutical companies may argue that the quality of
the branded drug is higher than that of the pharmaceutical
compounding. The application dossier for Pedea® specif-
ically mentions that all components of the drug are in
agreement with the requirements from the European
Pharmacopoeia. They argue that in pharmaceutical com-
pounding, there is no quality control. Human errors can
be fatal, as illustrated by some newspaper articles added to
the application dossier. In another case, the applicant ar-
gued that the pharmaceutical compounding of 3,4-DAP is
not a suitable alternative for Firdapse®. An article from a
Dutch journal was added to the dossier for Wilzin® which
stated that more than a quarter of pharmaceutical com-
pounding in hospitals did not meet the minimum quality
requirements. Additionally, there was mention of a Dutch
lawsuit in which a Wilson’s disease patient took legal ac-
tion against his doctor and pharmacist due to chronic
under-dosing. Even so, the DRC appears not susceptible to
these arguments, often because the price of the pharma-
ceutical compounding is significantly lower. For example,
there is a five-fold difference between the daily price of
zincacetate and Wilzin®.
Media attention
Rare diseases and orphan drugs often appear in the
media. Unfortunately, the communication about the de-
velopment of upcoming orphan drugs is oversimplified
and overly positive which could influence the members
of the DRC in the decision making process.
“The communication about drugs in development is very
bad, without any nuance. If a trial has just started, it’s
like it has already succeeded, and people only hear that
part of the story and cherish illusions, think they are
being fooled, or don’t get what they deserve to have, but
in fact, it’s not even there yet”. [I2]
“And there is another group, the academics, which are
often forgotten! There are those who are forced by the
firms, but there are others who, without pressure, out of
pride for their own work, and also eagerness, start to
communicate about it [new treatment] way to soon. You
often see announcements that they found something in
Leuven or Ghent [location of Belgian universities] for the
treatment of this or that, but most of the time, it’s
yeaaars before registration is even possible. And the
media of course jump on it, but those academics have a
responsibility too, because they give hope to patients that
not always should be hoping”. [I4]
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no direct influence on the decision-making process.
“Well indirectly, it [media attention] creates awareness
about the problem, which is good and important, but I
think there is a big difference between being aware
and being influenced in the decision making”. [I1]
“The timing [of media attention] is often not in line
with the DRC, in general, if something happens, …
because the media, it’s created, either too soon, long
before a dossier is opened, and then a process is forced
because “we have to do something”, and then the DRC
leaves the decision to the Minister. Or when something
has gone wrong, or is about to go wrong, well yeah
“wrong”, … a negative decision”. [I6]
In 2013, the reimbursement of Soliris® for the treatment
of atypical hemolytic uremic syndrome was refused. Con-
troversy arose when the case of an aHUS patient was
shown in the media. Afterwards, it became clear that the
pharmaceutical company deliberately brought attention to
this case in the media with a view to influencing the reim-
bursement decision. Soliris® was later approved for reim-
bursement, by the Minister, after an unknown price
reduction, thereby overruling the negative advice from the
DRC. This may serve as an example in which media atten-
tion might have influenced the decision-making.
Innovative character
Pharmaceutical companies may argue that the innovative
character of the drug may warrant reimbursement. The
application dossier for Firazyr® mentions that the drug
recently has been pronounced “the year’s best idea in
health” by a leading medical journal. Yet, according to
interviewees, the level of innovativeness of a new drug is
not considered in reimbursement decisions.
“What is meant by innovation? Everyone can say, it’s
innovative, but in what area? Is it something new, a
drug for something without [therapeutic] options? Or
is it something for which we have an alternative, but
with less side effects, or more user-friendly? Ok, those
are also innovations, but we also have to look, does the
innovation justify the price? It’s a balance between
all factors”. [I5]
“If you have a new method of action, then it is
innovative, but it’s not because it’s innovative that it
actually works, I mean clinically works. Innovation is
perceived by the general public as something that
has a positive effect on life expectancy or quality of
life”. [I3]Economic importance
Investments made by the government or the pharma-
ceutical company in the development of the drug may
well be considered in reimbursement decisions.
“In my experience, if research is supported by the
government, to support the development of orphan
drugs, that’s good, but it also leads to the expectation
that reimbursement is the icing on the cake”. [I1]
“I remember that, in a few dossiers, employment in
Belgium was specifically mentioned by the company”. [I1]
“I think that companies often mention that their
company has research and development in Belgium,
which creates employment, and saying there are many
employers in Belgium. (…) What they are basically
saying is, “do you want to make it more difficult for us
than other countries?” [I2]
For example, it is stated in the reimbursement dossier
for Myozyme® that the marketing of a 200 mg vial (which
is better suited for dosage titration) will depend on the
successful production of the drug in Geel, Belgium.
“The support is not only for innovation or logistics or
infrastructure, but also for whole departments, and
specialized nurses. There are also investments in
fundamental research … and in training of doctors”.
[I4 and I6]
For example, the drug Gliolan® may only be used by
neurosurgeons that have completed a training course.
The application dossier mentions that ten Belgian doc-
tors already completed the course prior to the applica-
tion for reimbursement.
Ethical arguments
Ethical arguments, such as the rule of rescue, right to
treatment and equity in access to treatment often sur-
face during complex reimbursement decisions [25-27].
Interviewees expressed difficulties they encounter when
balancing these ethical arguments.
“It’s difficult, certainly if it involves children with
life-threatening diseases, to keep the discussion
purely scientific (…) As a doctor, it is not always
straightforward (…) on the one hand you want to
leave “no stone unturned” for each individual
patient, but on the other hand, we have to look at the
bigger picture and balance some things. (…) I think
maybe that is the core of the problem, because it’s
about individual patients, children or adults, if it’s
about larger groups than it remains anonymous and
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“We had a discussion in the DRC once, in which we
said, this [decision about the reimbursement of an
enzyme replacement therapy for children] is in fact an
ethical discussion, and we are not an ethical
committee”. [I2]
Political climate
In the final reimbursement decision, the Minister of
Social Affairs can deviate from the advice of the DRC
out of social and/or budgetary reasons.
“The Minister can deviate [from the advice of the DRC]
out of social or economic reasons. (…) But that is a wide
concept, it’s not defined, and we don’t know it either”. [I3]
Interviewees are unclear as to the influence of the pol-
itical climate on the decision-making.
“I think that it [upcoming elections] plays a role, but
… we have so many elections, almost every year is an
important election year”. [I2]
“You can’t expect an answer from us here, but
honestly, I would be surprised”. [I6]
Discussion
This study provides an analysis of which official (i.e.
therapeutic value, budget impact, price and impact in
clinical practice) and non-official factors (i.e. pricing and
reimbursement in other countries, interference by pa-
tient organisations and experts, arguments related to
quality, media attention, innovative character, economic
importance, ethical arguments and the political climate)
may have influenced reimbursement decisions for or-
phan drugs in Belgium. To that end, we provided an
overview of relevant quotes made by (current or past)
members of the DRC and documented how these differ-
ent factors were put forward and interpreted by both ap-
plicant and the DRC in the reimbursement dossiers.
Our qualitative results confirm previous quantitative find-
ings from the international literature. Dakin et al. found
that the number of randomized controlled trials and the
presence of a submission from a patient organization are
predictors of a positive evaluation by NICE [20,28]. The
study from Denis et al. concluded that evidence of thera-
peutic value tended to be very limited and often derived
from few clinical studies [13]. Dupont and Van Wilder
found that the same quality of clinical evidence as required
for medicines for common indications was not required for
orphan drugs. Furthermore, with respect to dosing, they
uncovered that especially for metabolic diseases, dose-finding studies were lacking [15]. The reimbursement of
Cerezyme® was initially refused in Israel due to high cost.
Currently, researchers are trying to establish whether
lowering the dose to less than a quarter of manufac-
turer’s dose is feasible (i.e. without a change in effective-
ness with a view to significant cost savings [9]. Finally,
Cerri et al. found no significant association between
whether or not the decision by NICE was made in an
election year [10]. From this, it appears as if similar
non-official factors play a role in the reimbursement of
non-orphan drugs, although no comparison has been
made between orphan and non-orphan drugs.
Multi-criteria decision analysis (MCDA) has been pro-
posed as a framework to evaluate new (orphan) drugs
for reimbursement based on a combination of several
criteria. In an MCDA, the relevant criteria and their im-
portance are defined a priori. Criteria such as availability
of existing treatments, treatment safety, manufacturing
complexity have been proposed [11,29]. These proposed
criteria are however not exhaustive. Some factors iden-
tified in this study might be added to an MCDA as a
measurable criterion, for example, if the drug creates
employment and if the drug is reimbursed in other
countries. Other factors such as media attention or polit-
ical climate are less or even non quantifiable. Weights
should be attributed to each of the criteria based on the
values attached to them by society [29]. In any case, trans-
parency is needed to enhance consistency in the decision-
making process [11].
This study provides insight into the different factors that
might be taken into consideration during reimbursement
decisions for orphan drugs in Belgium. Because of the
qualitative nature of the study, we are unable to quantify
the effect of each factor on reimbursement decisions. Fur-
thermore, it is most likely that there is interplay between
the different factors.
Conclusion
This study has shown that reimbursement of orphan
drugs in Belgium is possibly influenced by a combination
of official and non-official factors. The identification of
these factors is a crucial step in the development of a
transparent and consistent framework which will guide fu-
ture decision-making for reimbursement of orphan drugs.Additional file
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